- Home
- GLAD vs AUTL Comparison
GLAD vs AUTL Comparison
Compare GLAD & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLAD | AUTL |
|---|---|---|
| Founded | 2001 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 482.1M | 368.6M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | GLAD | AUTL |
|---|---|---|
| Price | $21.44 | $1.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $22.33 | $8.33 |
| AVG Volume (30 Days) | 198.8K | ★ 3.8M |
| Earning Date | 11-17-2025 | 11-12-2025 |
| Dividend Yield | ★ 9.23% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.55 | N/A |
| Revenue | ★ $89,122,000.00 | $51,128,000.00 |
| Revenue This Year | $13.04 | $658.11 |
| Revenue Next Year | $9.55 | $91.34 |
| P/E Ratio | $8.42 | ★ N/A |
| Revenue Growth | N/A | ★ 406.67 |
| 52 Week Low | $18.76 | $1.11 |
| 52 Week High | $30.43 | $2.88 |
Technical Indicators
Market Signals| Indicator | GLAD | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 66.47 | 59.11 |
| Support Level | $21.27 | $1.46 |
| Resistance Level | $21.60 | $1.66 |
| Average True Range (ATR) | 0.33 | 0.10 |
| MACD | 0.08 | 0.03 |
| Stochastic Oscillator | 82.11 | 84.04 |
Price Performance
Historical ComparisonAbout GLAD Gladstone Capital Corporation
Gladstone Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objectives are to, achieve and grow current income by investing in debt securities of established businesses that would provide stable earnings and cash flow to pay expenses, make principal and interest payments on its outstanding indebtedness, and make distributions to stockholders that grow over time; and provide its stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses that can grow over time to permit it to sell its equity investments for capital gains.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.